PACIRA BIOSCIENCES, INC. Proceeds from Lines of Credit
PACIRA BIOSCIENCES, INC. (PCRX) reported Proceeds from Lines of Credit of $101.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-02-26
- PACIRA BIOSCIENCES, INC. proceeds from lines of credit for the quarter ending 2025-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. proceeds from lines of credit for the quarter ending 2024-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. proceeds from lines of credit for the quarter ending 2024-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. proceeds from lines of credit for the quarter ending 2024-06-30 was $0.00.
- PACIRA BIOSCIENCES, INC. proceeds from lines of credit for fiscal 2025 was $101.00M.
- PACIRA BIOSCIENCES, INC. proceeds from lines of credit for fiscal 2024 was $0.00.
- PACIRA BIOSCIENCES, INC. proceeds from lines of credit for fiscal 2023 was $0.00.
- PACIRA BIOSCIENCES, INC. proceeds from lines of credit for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $101.00M 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $101.00M 10-Q · filed 2025-11-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | -$149.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $0.00 10-Q · filed 2024-07-30 | -$149.55M derived: sum of 3 quarters · filed 2026-02-26 | -$149.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | -$149.55M derived: sum of 2 quarters · filed 2026-02-26 | -$149.55M derived: sum of 3 quarters · filed 2026-02-26 | -$149.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$149.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$149.55M derived: sum of 2 quarters · filed 2026-02-26 | -$149.55M derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 derived: sum of 2 quarters · filed 2024-11-06 | $149.55M 10-Q · filed 2024-11-06 | $149.55M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | $149.55M 10-Q · filed 2024-07-30 | $149.55M derived: sum of 3 quarters · filed 2024-07-30 | $149.55M derived: sum of 4 quarters · filed 2024-07-30 |
| 2023-03-31 | $149.55M 10-Q · filed 2024-05-07 | $149.55M derived: sum of 2 quarters · filed 2024-05-07 | $149.55M derived: sum of 3 quarters · filed 2024-05-07 | $149.55M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 derived: sum of 3 quarters · filed 2023-11-02 | $0.00 10-K · filed 2023-02-28 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-03 | |||
| 2021-12-31 | $363.75M 10-K · filed 2023-02-28 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | |||
| 2010-09-30 | $5.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $11.25M 10-Q · filed 2011-10-31 | ||
| 2010-06-30 | $5.63M 10-Q · filed 2011-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |